Published in Gene Therapy Weekly, September 1st, 1997
The finding has major implications for the treatment of multiple sclerosis and other demyelinating diseases.
"Clearly, if protective immunization can be established with a single TCR antagonist peptide which itself is nonpathogenic, antagonizes specific pathogenic Th1 cells, and induces regulatory T cells, it may provide a desirable therapeutic option for use in the treatment of many autoimmune diseases," wrote Lindsay B. Nicholson and colleagues of Brigham and Women's Hospital and Harvard Medical School,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.